Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study

Reilmann, Ralf; Anderson, Karen E.; Feigin, Andrew; Tabrizi, Sarah J.; Leavitt, Blair R.; Stout, Julie C.; Piccini, Paola; Schubert, Robin; Loupe, Pippa; Wickenberg, Anna; Borowsky, Beth; Rynkowski, Gail; Volkinshtein, Rita; Li, Thomas; Savola, Juha-Matti; Hayden, Michael; Gordon, Mark Forrest

dc.contributor.author	Reilmann, Ralf
dc.date.accessioned	2024-07-11T13:11:33Z
dc.date.available	2024-07-11T13:11:33Z
dc.date.issued	2024
dc.identifier.issn	1474-4422
dc.identifier.uri	http://hdl.handle.net/10900/154959
dc.language.iso	en	de_DE
dc.publisher	New York : Elsevier Science Inc	de_DE
dc.relation.uri	http://dx.doi.org/10.1016/S1474-4422(23)00454-4	de_DE
dc.subject.ddc	610	de_DE
dc.title	Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study	de_DE
dc.type	Article	de_DE
utue.quellen.id	20240422000000_00386
utue.publikation.seiten	243-255	de_DE
utue.personen.roh	Reilmann, Ralf
utue.personen.roh	Anderson, Karen E.
utue.personen.roh	Feigin, Andrew
utue.personen.roh	Tabrizi, Sarah J.
utue.personen.roh	Leavitt, Blair R.
utue.personen.roh	Stout, Julie C.
utue.personen.roh	Piccini, Paola
utue.personen.roh	Schubert, Robin
utue.personen.roh	Loupe, Pippa
utue.personen.roh	Wickenberg, Anna
utue.personen.roh	Borowsky, Beth
utue.personen.roh	Rynkowski, Gail
utue.personen.roh	Volkinshtein, Rita
utue.personen.roh	Li, Thomas
utue.personen.roh	Savola, Juha-Matti
utue.personen.roh	Hayden, Michael
utue.personen.roh	Gordon, Mark Forrest
dcterms.isPartOf.ZSTitelID	Lancet Neurology	de_DE
dcterms.isPartOf.ZS-Issue	3	de_DE
dcterms.isPartOf.ZS-Volume	23	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE